Utreloxastat
Product Specifications
Product Name Alternative
PTC857
UNSPSC Description
Utreloxastat (PTC857) is an orally active 15-lipoxygenase inhibitor that can cross the blood-brain barrier. Utreloxastat is a weak inhibitor of CYP1A2 and 2B6 with an IC50 > 5.3 μM. Utreloxastat reduces oxidative stress and inhibits the consumption of reduced glutathione and ferroptosis. Utreloxastat can be used in the study of neurodegenerative diseases characterized by high levels of oxidative stress and mitochondrial pathology, such as amyotrophic lateral sclerosisc[1][2].
Target Antigen
Cytochrome P450; Ferroptosis; Lipoxygenase; α-synuclein
Type
Reference compound
Related Pathways
Apoptosis;Metabolic Enzyme/Protease;Neuronal Signaling
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/utreloxastat.html
Purity
99.69
Solubility
DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)
Smiles
O=C1C(C)=C(C)C(C(C)=C1CCCCCCCCC)=O
Molecular Weight
276.41
References & Citations
[1]Andrew W. Hinman, et al. 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS. WO2020081879A2.|[2]Gao L, et al. First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis. Clin Pharmacol Drug Dev. 2023 Feb;12(2):141-151.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-132845/Utreloxastat-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-132845/Utreloxastat-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
1213269-96-5
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
